Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
* J, E1 x* C: C Q9 @$ Y8 Q4 \* m: |3 h
& w# y1 u4 j- r) j
Sub-category:2 x8 U8 l# ?$ l& b3 {9 U
Molecular Targets
8 Q9 x5 P& K; o: W {# {' b( c+ H$ e; `6 _, `! o" o
3 s( N. B2 h9 ^! w; Y
Category:% n# n; H! C; m5 y7 j! q& D1 F
Tumor Biology
h' H8 v5 Y0 A) a& R! `
( ~; w% }1 [1 j! M; w: _- R. v
% d8 s. E( j8 {8 J; U. L- KMeeting:
3 X% {5 G8 E: o/ U: A2011 ASCO Annual Meeting & ?- m2 D6 F6 Z0 l/ Z2 ?( a* Q9 [
, K1 B! q6 x$ \" X5 J! H; [
4 W8 g5 I- {8 I8 }* ]8 Y+ A& j9 a
Session Type and Session Title:/ i9 N: V& Q9 L( p' }
Poster Discussion Session, Tumor Biology ( M$ @& H) t4 `9 M
: Z& |5 _& N3 R, ^
( x2 o- ^3 ]8 l$ fAbstract No:
* \4 v4 M9 W: t" q10517 - e% N& Q y) W
* h1 x) O8 i0 ?( }4 m( f& S2 @! e( k) C: A
Citation:
! k3 x8 ~3 ~1 u( _# v. SJ Clin Oncol 29: 2011 (suppl; abstr 10517) 6 U/ f1 K5 K8 q, c- _ [
$ V0 S3 X( y k9 p
& H- K$ i- J' B8 C EAuthor(s):" k0 ?5 M3 @6 A8 B% C# h4 K
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China " U& z1 l8 u5 H/ x
" x9 y8 D+ I: U! U
& S |5 B9 H3 c2 z* d% i
& q9 A, z" p* L: XAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.' Y/ k' R6 {4 ?% ~
( w2 H' F: O; N1 ]& h0 M8 a6 {Abstract Disclosures" M( @; a5 F3 O7 N$ ~7 r: d; G
, @1 c* E! v- p t- OAbstract:5 ?6 G# K8 G7 y* z- \
0 U1 ~+ J/ a( S7 k1 I2 ^9 Z3 w0 Q& \5 C' u
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.4 o9 {( S3 _# Y6 E* o
; f8 c7 o! ~3 W7 K1 A
8 x! {4 \6 G; Y% h; c! @ |